Continuous Avoidance Cost in Biosimilar: A Budget Impact Analysis on the Basis of Clinical Trial Model and RWD in Brazil / LATAM / LMIC .
Author(s)
Gabriel Kenzo Tanaka, RESEARCHER1, ELIO TANAKA, Sr., MD2, Sueli Kazue Muramatsu Pereira, RESEARCHER3, Hugo Nidahara, RESEARCHER3, Romeu Kuabara, MD4, Rogerio Scarabel Barbosa, RESEARCHER4, Freddy Luis Ventura TORREZ, RESEARCHER3, Raquel Ferreira Scholz, RESEARCHER3.
1MEDICAL AUDIT, TNK, CURITIBA PR, Brazil, 2MEDICAL AUDIT, TNK MEDICAL AUDIT INSTITUTION, CURITIBA, Brazil, 3TNK, CURITIBA PR, Brazil, 4TNK, CURITIBA , PR, Brazil.
1MEDICAL AUDIT, TNK, CURITIBA PR, Brazil, 2MEDICAL AUDIT, TNK MEDICAL AUDIT INSTITUTION, CURITIBA, Brazil, 3TNK, CURITIBA PR, Brazil, 4TNK, CURITIBA , PR, Brazil.
OBJECTIVES: Innovative biosimilars, such as pegylates, alternative presentations, such as subcutaneous instead of intravenous, are an alternative to biologics with high prices. The extent of the savings resulting from the use of biosimilars depends on their price and acceptance, which are largely shaped by pricing, reimbursement, and demand-side policies. The study aimed to evaluate the financial impact of the Pegfilgrastim Biosimilar (B-PEG) among biosimilars from the point of view of the private health system.
METHODS: An Excel-based budget impact model was developed to estimate the financial impact by introducing a B-Peg in BRAZIL over a 5-year time horizon. Comparators included long-acting and short-acting G-CSFs. In a total French population and patients estimated to be treated with G-CSFs annually were used, as a percentage, for comparison. Based on the Oncology Care Model Framework, RWE over 1 year, a total of 121 out of 500 patients received G-CSF prophylaxis, resulting in cost savings ranging from $0.54 million (U.S. dollar) (short-acting, e.g., filgrastim) to $1.68 million (long-acting, e.g., pegfilgrastim) when switching to B-Peg. Data from a private HMO health network in Brazil were analyzed .
RESULTS: In a total Brazil population of ~220 million, an estimated 244,000 patients are treated with G-CSFs annually. It means 0.15%. The annual number of patients to be treated with B-Peg in Brazil was estimated at 48,800, 49,950, 51,500, 53,200, and 55,560 in years 1 to 5, respectively. The results in the use of biosimilars (including B-Peg) at HMO reach an evasion cost of R$ 13,093,326.53 in 2023 (~USD 2,600 thousand). (ratio 1:5)
CONCLUSIONS: The study demonstrates benefits of B-Peg. The savings are substantial, benefits population-based outcomes at a lower cost. The introduction of a B-Peg and others are cost savings, allows administrative switch, and show no nocebo effect for the Brazilian Healthcare System.
METHODS: An Excel-based budget impact model was developed to estimate the financial impact by introducing a B-Peg in BRAZIL over a 5-year time horizon. Comparators included long-acting and short-acting G-CSFs. In a total French population and patients estimated to be treated with G-CSFs annually were used, as a percentage, for comparison. Based on the Oncology Care Model Framework, RWE over 1 year, a total of 121 out of 500 patients received G-CSF prophylaxis, resulting in cost savings ranging from $0.54 million (U.S. dollar) (short-acting, e.g., filgrastim) to $1.68 million (long-acting, e.g., pegfilgrastim) when switching to B-Peg. Data from a private HMO health network in Brazil were analyzed .
RESULTS: In a total Brazil population of ~220 million, an estimated 244,000 patients are treated with G-CSFs annually. It means 0.15%. The annual number of patients to be treated with B-Peg in Brazil was estimated at 48,800, 49,950, 51,500, 53,200, and 55,560 in years 1 to 5, respectively. The results in the use of biosimilars (including B-Peg) at HMO reach an evasion cost of R$ 13,093,326.53 in 2023 (~USD 2,600 thousand). (ratio 1:5)
CONCLUSIONS: The study demonstrates benefits of B-Peg. The savings are substantial, benefits population-based outcomes at a lower cost. The introduction of a B-Peg and others are cost savings, allows administrative switch, and show no nocebo effect for the Brazilian Healthcare System.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE245
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Value of Information
Disease
SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), SDC: Oncology, SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain), STA: Biologics & Biosimilars